PROCEPT is taking HYDROS Aquablation outside the U.S.

PROCEPT BioRobotics announced the international launch of the HYDROS Robotic System on March 12, 2026, beginning in the United Kingdom with additional international expansion planned during 2026. HYDROS is the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia, or BPH.

PROCEPT BioRobotics was founded in 2007 and is headquartered in San Jose. The company builds surgical robotics for urology and manufactures the AQUABEAM and HYDROS robotic systems. Its commercial focus is Aquablation therapy, which combines real-time ultrasound imaging, treatment planning, automated robotic execution, and a heat-free waterjet to remove prostate tissue.

BPH treatment is a high-volume clinical market where surgical adoption depends on physician training, hospital purchasing, reimbursement, patient outcomes, and evidence that the system can preserve quality-of-life measures while relieving symptoms. PROCEPT says BPH affects about 40 million men in the United States, with Aquablation supported by roughly 250 peer-reviewed publications - the clinical evidence base that international hospitals will evaluate before converting to a new surgical platform.

HYDROS adds an AI-enabled layer to that installed clinical story. The company describes AI-interpreted real-time ultrasound imaging and advanced image-guided treatment planning that help surgeons deliver anatomy-specific therapy with robotic precision and reproducibility. In the UK, PROCEPT framed the launch around NICE-recommended Aquablation therapy and quoted consultant urological surgeon Neil Barber on real-time ultrasound guidance and robotic assisted planning.

The proof boundary is international rollout, not a new clinical trial result. Public material names the UK as the first international HYDROS launch market and describes additional expansion plans, but it does not disclose UK hospital count, system placements, procedure volume, country-by-country reimbursement, or early utilization for HYDROS outside the United States.

The competitive field includes TURP and laser-based BPH procedures, Boston Scientific's Rezum therapy, Teleflex's UroLift system, Olympus and Karl Storz endoscopic workflows, and robotic surgery platforms that could move deeper into urology procedures. PROCEPT's distinction is the dedicated BPH robotics stack: ultrasound-guided planning, heat-free waterjet tissue removal, and robotic execution built around prostate anatomy rather than a general surgical robot.

HYDROS pushes PROCEPT's story from domestic surgical robotics adoption into global category formation for Aquablation. If international hospitals convert clinical evidence into routine procedure volume, PROCEPT can make BPH robotics less of a specialized system sale and more of a repeatable urology platform across markets.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to tips@korthos.xyz or reach out on X at @agkorthos.